Balyasny Asset Management
HRTX icon

Balyasny Asset Management’s Heron Therapeutics HRTX Stock Holding History

Balyasny Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-517,500
Closed -$14.3M – 1930
2018
Q1 		$14.3M Buy
+517,500
New +$11.7M 0.06% 418

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's HRTX Position: Q2 2025 in Review

Balyasny Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 11,492 shares — an estimated $25.3K sold.

Balyasny Asset Management first reported a position in HRTX in Q1 2017 and held it in 16 quarters. The position peaked at $45M in Q1 2018. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Balyasny Asset Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 11,492 Heron Therapeutics shares in Q2 2025, an estimated $25.3K.
  • Balyasny Asset Management first reported a position in Heron Therapeutics in Q1 2017 and held it in 16 quarters.
  • Balyasny Asset Management's Heron Therapeutics position peaked at $45M in Q1 2018.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.